Professor Linong Ji, the Leading Principal Investigator of GLORY-1, Peking University People's Hospital, stated, "Obesity is a chronic disease that demands a coordinated societal response
Reversal after the fact was nearly impossible
REMODEL, A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (NCT04865770)
Earlier framings of "0.34 partial agonist at GCGR" or "0.4 softened agonist at GLP-1R" mistook potency ratios (EC50_LY EC50_native) for efficacy multipliers (E_max_LY E_max_native) and are retracted
Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs
GLP-1 (glucagon-like peptide-1) is a hormone that helps regulate appetite and food intake